AVXL News & Events

The company states: "Anavex Life Sciences is unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 by the prescribed May 11, 2026 due date without unreasonable effort and expense due to the circumstances described below. As previously disclosed in the Company's Current Report on Form 8-K filed on May 6, 2026, a special committee composed of independent directors of the Board of Directors terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy. On May 4, 2026, the Special Committee appointed Dr. Terrie Kellmeyer as Interim Chief Executive Officer. Until the Special Committee and the Company complete their review of certain matters related to the termination of Dr. Missling and Dr. Kellmeyer has had sufficient opportunity to review the Form 10-Q prior to its certification and filing, the Company will be unable to complete its preparation and review of the Form 10-Q without unreasonable effort or expense. The Special Committee and the Company are working diligently to complete their review so that the Company can file the Form 10-Q."

Anavex Life Sciences announced that its board has appointed former senior VP of clinical development and current senior advisor Terrie Kellmeyer as interim CEO. The appointment follows the departure of president and CEO Christopher Missling from the company on April 30 and the board's request for his resignation. Anavex said it expects to file a Form 12b-25 to extend the filing date of its Form 10-Q for the quarter ended March 31, as it does not expect to meet the SEC due date.